Antineoplastic

Antineoplastics
Tabine series
2-Deoxy-D-ribose [intermediate]
2-Fluoroadenosine [HOT] [intermediate]
Zomib series
(R)-BoroLeu-(+)-Pinanediol-CF3COOH [HOT] [intermediate]

 

 

 

 

(R)-BoroLeu-(+)-Pinanediol-CF3COOH,179324-87-9,Bortezomib intermediate
(R)-BoroLeu-(+)-Pinanediol-CF3COOH
(R)-BoroLeu-(+)-Pinanediol-CF3COOH,179324-87-9,Bortezomib intermediate
CAS
179324-87-9
Molecular Formula
C15H28BNO2.C2HF3O2
Molecular Weight
379.224
Assay
97%
API
Bortezomib
Certificate of analysis
(R)-BoroLeu-(+)-Pinanediol-CF3COOH,179324-87-9,Bortezomib intermediate
View via PDF file
(R)-BoroLeu-(+)-Pinanediol-CF3COOH,179324-87-9,Bortezomib intermediate
Specification
Items
Specification
Test result
Appearance
White or off-white crystalline powder
Complies
Identification
IR
Complies
Specific rotation
+9.0° to 11.0°
+10.2°
Water
Not more than 2.0%
0.2%
Assay
>97.0%
100.18%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

List of solvents used in manufacturing:
01
tert-Butyl methyl ether
C5H12O
02
Dichloromethane
CH2Cl2
03
THF
C4H8O
04
Methylcyclohexane
C7H14
05
Hexane
C6H14
06
Isopropyl ether
C6H14O
Packing
(R)-BoroLeu-(+)-Pinanediol-CF3COOH,179324-87-9,Bortezomib intermediate
Packing 1
1g
Packing 2
10g
Packing 3
500g
   
   
   
Related Zomib series
(R)-BoroLeu-(+)-Pinanediol-CF3COOH [HOT] [intermediate]
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product((R)-BoroLeu-(+)-Pinanediol-CF3COOH,179324-87-9,Bortezomib intermediate).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.